Shares of Mindray (NYSE:MR) dropped 6.8% after it reported lower-than-expected 1st-quarter sales and slower growth outside the People’s Republic. However, after plummeting to $37.01 May 7, shares in the Chinese medical device company bounced back to top its pre-earnings close, reaching $41.67 May 17.*

Shenzhen, China-based Mindray posted profits of $57.4 million, or 48¢ per share, on sales of $242.1 million during the 3 months ended March 31, for a bottom-line gain of 56.8% and top-line growth of 10.5%.

Adjusted to exclude 1-time items, earnings per share were 53¢, a penny shy of expectations on Wall Street.

Revenues grew 21.2% in China during the quarter, but only 2.8% in international markets, which accounted for 54% of total revenues, according to Mindray.

Mindray maintained its guidance for the rest of the year, saying it expects to post "at least" 17% sales growth and adjusted profit growth of 15%, excluding tax benefits.

*Correction, May 20, 2013: Due to an editor’s error, this story originally omitted the share-price impact of Mindray’s 1st-quarter earnings report. Return to the corrected sentence.